Sir,

The report by Stephan *et al*. on a patient with lamotrigine-induced hypersensitivity syndrome and histologic features of CD30^+^ lymphoma suggest a complex interplay of a known infectious agent human herpesvirus-6 and hitherto unknown human leukocyte antigen (HLA) haplotype interacting with CD3^+^ T cells of the immune system.\[[@ref1]\] Such case reports throw light into possible mechanisms responsible for such serious cutaneous adverse reactions (SCARs). Lamotrigine, including other anticonvulsants, and allopurinol are well known to cause SCARs but unlike HLA-B\*3:01 that increases allopurinol sensitivity, the HLA association(s) for most drugs remain unknown. Several other drugs including the biologics such as anti-tumor necrosis factor-α (TNF-α) have been reported to cause a cutaneous pseudolymphoma like lesion due to intense CD30 positivity \[[Table 1](#T1){ref-type="table"}\].
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Drug-reactive T cells are thought to cause SCARs, and CD30/Ki-1 is a cell-surface molecule of the TNF receptor family that is expressed on a subset of activated T cells and B cells.\[[@ref2]\] This cell surface molecule is up-regulated on T cells when exposed to allogeneic antigens, and these CD30^+^ T cells produce interleukin-5 (IL-5) and interferon-g and exhibit enhanced B-cell helper activity. If the drug behaves as the allogeneic antigen, the ensuing cytokine storm with IL-5 would lead to eosinophil recruitment and drug rash, eosinophilia, systemic symptoms.\[[@ref3]\] The other cell of interest is the mast cell that can produce and release numerous powerful mediators (serine proteinases tryptase and chymase, histamine, heparin, leukotriene C4, prostaglandin D2, wide range of cytokines, chemokines) that enable their participation in both adaptive and innate immune responses. Mast cells can express functional CD30 ligand (CD30L/CD153), a member of the TNF superfamily, that could interact with activated T cells. CD30 expression is also seen in activated lymphoid cells and cell infiltrates of atopic dermatitis, scabies, reactions to insect bites, graft versus host disease, infiltrates of viral infections of herpes simplex, orf virus and molluscum contagiosum.\[[@ref4]\] Hence, CD30 staining patterns in a cutaneous lymphoid infiltrate should be interpreted with caution to avoid misdiagnosis of malignancy.

Clinicians should take note that even cytopenias or features of hemophagocytic lymphohistiocytosis could be part of SCARs and immediate discontinuation of offending drug(s) should be the first line of management. This is more difficult with newer drugs such as the mean interval between first administration of anti-TNF-α and appearance of CD30^+^ skin lesions or pseudolymphoma was longer (mean 218.8 days) than that of nonbiologic drugs.\[[@ref5]\] Until robust biomarkers or HLA associations are available to prevent SCARs, patient education remains the key to prevent unnecessary morbidity and mortality associated with drug reactions.

 {#sec2-1}

Financial support and sponsorship {#sec3-1}
---------------------------------

Nil.

Conflicts of interest {#sec3-2}
---------------------

There are no conflicts of interest.
